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an Serologic Markers
f Fibrosis Reveal an
rrhythmogenic Ventricular
ubstrate in Nonischemic
ilated Cardiomyopathy?*
regory M. Marcus, MD, MAS
an Francisco, California
here is general agreement that left ventricular ejection
raction (EF) remains the best available predictor in helping
o select appropriate patients for a primary prevention
mplantable cardioverter-defibrillator (ICD) (1). However,
t is also widely recognized that this measurement alone is
uboptimal, lacking in both sensitivity and specificity (2). In
articular, primum non nocere (“first, do no harm”) be-
omes a particularly relevant consideration when we face
atients suffering from the complications of an ICD im-
lantation with the knowledge that they might never need
he device. This issue is relevant not only to patients that are
andidates for their initial primary prevention ICD but
ncreasingly to those ICD patients who have never exhibited
malignant ventricular arrhythmia presenting for a second,
hird, or fourth procedure because of a lead fracture, device
ecall, or generator at the elective replacement interval.
etter predictors of incident malignant ventricular arrhyth-
ias are needed.
See page 2753
These issues are particularly pertinent to patients with
onischemic dilated cardiomyopathy (NIDC) for several
easons. First, the data supporting primary prevention ICDs
n this population are not as robust as the data for those with
reduced EF due to coronary disease (1,3–6). Second, tools
sed to help with risk stratification, such as invasive elec-
rophysiology testing, are likely not as useful in patients with
IDC (7). Finally, because many of the youngest patients
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiology, Electrophysiology Section, University of Cali-i
ornia, San Francisco, California. Dr. Marcus has received research support and
peaker fees from St. Jude Medical and Biotronik.eeting guideline criteria for primary prevention ICDs will
ore often have a nonischemic than an ischemic etiology,
IDC patients might more often have the most to gain
rom a new clinically useful predictor of malignant ventric-
lar arrhythmias.
Much research has sought to determine useful tests for
udden arrhythmic death risk stratification. Whether based
n electrophysiologic parameters (such as QRS duration,
nvasive electrophysiology testing, the signal averaged elec-
rocardiogram, and micro-volt T wave alternans) or auto-
omic parameters (such as heart rate variability, heart rate
urbulence, or baroreflex sensitivity), none have proven to
rovide widely applicable accuracy (7,8). Recently, methods
o better understand the structural substrate have been
nvestigated. Interesting data suggest that the nature of the
entricular scar as determined by magnetic resonance imag-
ng might reveal those hearts at particularly high risk, even
n those with NIDC (9,10). Because cardiac magnetic
esonance imaging might not be a feasible screening tool for
rimary prevention ICD patients, the search for less expen-
ive and more easily obtained measures of arrhythmogenic
yocardial scar has begun.
In this issue of the Journal, Kanoupakis et al. (11) describe
heir study investigating the utility of several markers of
brosis, C-terminal propeptide of collagen type-1, C-terminal
elopeptide of collagen type-1, matrix metalloproteinase-1, and
he tissue inhibitor of matrix metalloproteinase-1, as predictors
f appropriate ICD therapies in 70 NIDC patients. These
erologic markers reflect the synthesis and degradation of
ype-1 collagen, the most abundant form of collagen in
yocardium. The underlying hypothesis is that a snapshot
iew of these peripheral serum levels would provide a window
nto understanding the arrhythmic potential of myocardial scar.
Fourteen of the 70 patients experienced at least 1 appro-
riate ICD therapy over 1 year of follow-up. Although no
ifferences in demographic data, associated medical condi-
ions, or medications between those with and without the
utcome were observed, 3 of the 4 serologic markers were
ignificantly higher in those with an appropriate ICD
herapy than in those without. These differences were not
nly statistically significant but also exhibited a potentially
linically useful separation in distributions, particularly for
-terminal telopeptide of collagen type-1. This appropri-
tely motivated an assessment of receiver-operating charac-
eristics curves, with a suggestion that these markers might
xhibit excellent test characteristics.
In addition to addressing an important topic and provid-
ng early research toward a potentially new method in risk
ssessment, this study has several strengths: the population
s quite homogenous, comprised of only NIDC patients.
hree markers exhibited similar patterns, providing consis-
ency in support of their hypothesis. There was also no
pparent loss to follow-up, and the outcome was based on
bjective and measurable data. However, before these find-
ngs are considered for integration into clinical practice or
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June 15, 2010:2760–1 Serologic Markers of Fibrosisven further study, it is important to highlight several
mportant limitations.
First, the outcome was appropriate ICD therapy, an
mperfect surrogate for mortality. In addition, the primary
utcome was heterogeneous, comprising either antitachy-
ardia pacing or ICD shock. Although most patients with a
rimary outcome experienced an ICD shock, arguably a
linically relevant outcome given the associated severe dis-
omfort, some of the antitachycardia pacing events might
ave represented treatment for ventricular tachycardia that
ould have spontaneously resolved.
Second, as is the case with essentially any observational
tudy, residual confounding must always be considered as an
xplanation for positive findings. The groups seemed to be
ell-balanced by all measured clinical characteristics, but a
ack of statistical significance between such characteristics
oes not eliminate the possibility of confounding. In addi-
ion, the variables assessed were not comprehensive. For
xample, body mass index was not reported. Could it be that
hese markers are increased in obesity and that obesity was
he true predictor of ICD therapy? To address unmeasured
nd unknown confounders, a randomized study is required.
Third, external validity or generalizability to our patients
n practice deserves consideration. All patients had evidence
f nonsustained ventricular tachycardia on Holter study or
nducible ventricular tachycardia with invasive electrophys-
ology testing. Per the most recent guidelines (1), based
rimarily on SCD-HeFT (Sudden Cardiac Death in Heart
ailure Trial) (6), NIDC patients can be appropriate can-
idates for primary prevention ICDs without any prior
vidence of ventricular arrhythmias. The mechanism of
entricular arrhythmias might be different in those with
rior evidence of nonsustained or inducible ventricular
achycardia compared with those with no known antecedent
rrhythmias, potentially making measurement of these
arkers less relevant in many NIDC patients. In addition,
his study was conducted in Crete. Perhaps the common
tiologies of NIDC in that single location are substantially
ifferent than elsewhere, and maybe the predictive ability of
hese fibrotic markers is uniquely conducive to NIDC of
hose particular etiologies. A larger study enrolling a more
iverse patient population would be needed to teach us
hether these same markers predict arrhythmias in patients
uch as the former methamphetamine user, the patient with
driamycin toxicity, the patient with a familial cardiomyop-
thy, or the hypertensive African American.
One apparent limitation involves the relatively small
ample size. However, it is important to emphasize that this
hould not increase the risk of a type I error. In other words,
small sample size or small number of outcomes is not
esponsible for spurious statistically significant associations.
owever, it does increase the likelihood of a type II errori.e., false negatives or insufficient power to detect a true yifference). In fact, the relatively small numbers might
xplain why clinical characteristics expected to be predictive
f the outcome, such as EF and New York Heart Associ-
tion functional class, were not significantly associated with
CD therapies.
In conclusion, although there is insufficient evidence to
onsider measurement of serologic markers of fibrosis as
seful predictors of appropriate ICD therapies in NIDC
atients in clinical practice, the intriguing findings described
n this report invite a potentially fruitful new line of
nvestigation. Ancillary studies of completed prospective
andomized trials with available baseline serum would
fficiently leverage existing resources and potentially validate
hese findings in a more definitive fashion.
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